IMR Press / RCM / Volume 22 / Issue 4 / DOI: 10.31083/j.rcm2204120
Open Access Review
Is a high calcific burden an indication, or a contraindication for Drug Coated Balloon?
Show Less
1 Department of Cardiology, Heartlands Hospital, University Hospitals Birmingham, B9 5SS Birmingham, UK
*Correspondence: sandeep270478@gmail.com (Sandeep Basavarajaiah)
Academic Editor: Mohammad Reza Movahed
Rev. Cardiovasc. Med. 2021, 22(4), 1087–1093; https://doi.org/10.31083/j.rcm2204120
Submitted: 13 June 2021 | Revised: 16 August 2021 | Accepted: 16 August 2021 | Published: 22 December 2021
(This article belongs to the Special Issue Drug-Coated balloons-The “leave nothing behind” strategy)
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

Drug coated balloons (DCB) are increasingly being used in coronary intervention. Most of their use is currently restricted to in stent restenosis, however, they are also being used to treat some de novo lesion subsets (especially small vessels) and in patients unable to take dual antiplatelet therapy beyond a month. Calcified lesions pose a significant challenge to coronary intervention from lesion preparation to the delivery of drug to the vessel wall. There are limited data on the use of DCB in calcified lesions. In this article, we have provided a detailed literature review on calcified lesions and the use of DCB including a case example.

Keywords
Coronary artery calcification
High calcific burden
Drug coated balloons
Drug eluting stents
Figures
Fig. 1.
Share
Back to top